Glucose Time-In-Range Development Evaluation (GIDE)
GIDE - Glucose Time-In-Range Development Evaluation
Sponsor: OptiScan Biomedical Corporation
Terminated
Loss of Funding
This NA trial investigates Dysglycemia and ICU and is currently terminated or withdrawn. OptiScan Biomedical Corporation leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
▶ Show 7 earlier versions
-
Nov 2021 — Dec 2022 [monthly]
Terminated NA
-
Jan 2021 — Nov 2021 [monthly]
Terminated NA
-
Nov 2020 — Jan 2021 [monthly]
Terminated NA
Status: Suspended → Terminated
-
Jun 2020 — Nov 2020 [monthly]
Suspended NA
Status: Recruiting → Suspended
-
Feb 2020 — Jun 2020 [monthly]
Recruiting NA
-
Oct 2019 — Feb 2020 [monthly]
Recruiting NA
-
Oct 2018 — Oct 2019 [monthly]
Recruiting NA
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- OptiScan Biomedical Corporation
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .